Boston Scientific wins Japanese approval for Promus stent system

Boston Scientific has received an approval from the Japanese Ministry of Health, Labor and Welfare, or MHLW, to market its Promus everolimus-eluting coronary stent system for the treatment of coronary artery disease.

The company plans to launch the product as soon as the reimbursement approval is granted, which is expected shortly.

According to The Boston Scientific, Promus stent is a next-generation, highly deliverable stent made from cobalt chromium, which allows for thinner struts without sacrificing strength or visibility. The combination of the polymer/stent platform and the controlled release of the everolimus drug is designed to provide excellent deliverability, a strong safety profile, low levels of late loss and improved efficacy.

The Promus stent is a private-labeled Xience V everolimus-eluting coronary stent system manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corporation by Boston Scientific. The Promus and Xience V Stents are identical products sold by the respective companies under different brand names.

Boston Scientific will continue to market its internally developed paclitaxel-eluting Taxus stent systems. Taxus and Promus are trademarks of Boston Scientific or its affiliates. Xience is a trademark of the Abbott Laboratories group of companies.

Maulik Nanavaty, president of Boston Scientific Japan, said: "We are very pleased to receive MHLW approval for the Promus stent in Japan. It complements our broad coronary intervention portfolio and reinforces our global leadership in the drug-eluting stent market. We remain committed to providing the most innovative products and therapies to the Japanese market."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: acquisition, disease, health, japan, labor, market, president, products, science